Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis.
about
Investigation of rheumatoid arthritis susceptibility genes identifies association of AFF3 and CD226 variants with response to anti-tumour necrosis factor treatmentBenefit of early treatment in inflammatory polyarthritis patients with anti-cyclic citrullinated peptide antibodies versus those without antibodiesBiologic efficacy optimization--a step towards personalized medicinePredictive factors of response to biological disease modifying antirheumatic drugs: towards personalized medicine.Association of the response to tumor necrosis factor antagonists with plasma type I interferon activity and interferon-beta/alpha ratios in rheumatoid arthritis patients: a post hoc analysis of a predominantly Hispanic cohortSerum Immunoglobulin G Levels to Porphyromonas gingivalis Peptidylarginine Deiminase Affect Clinical Response to Biological Disease-Modifying Antirheumatic Drug in Rheumatoid ArthritisCan Synovial Pathobiology Integrate with Current Clinical and Imaging Prediction Models to Achieve Personalized Health Care in Rheumatoid Arthritis?The predictive value of serum S100A9 and response to etanercept is not confirmed in a large UK rheumatoid arthritis cohort.Leveraging human genetics to develop future therapeutic strategies in rheumatoid arthritisAntibodies to citrullinated protein antigens (ACPAs): clinical and pathophysiologic significancePharmacogenetics and pharmacogenomics in rheumatology.Impact of psychological factors on subjective disease activity assessments in patients with severe rheumatoid arthritis.Genome-wide association analysis of anti-TNF drug response in patients with rheumatoid arthritis.Treatment of rheumatoid arthritis with tumour necrosis factor inhibitorsSmoking and rheumatoid arthritis.Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci.Lack of association of variants previously associated with anti-TNF medication response in rheumatoid arthritis patients: results from a homogeneous Greek populationImpact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohortThe status of rheumatoid factor and anti-cyclic citrullinated peptide antibody are not associated with the effect of anti-TNFα agent treatment in patients with rheumatoid arthritis: a meta-analysis.PTPN22: the archetypal non-HLA autoimmunity gene.Antibodies against cyclic citrullinated peptide don't decrease after 6 months of infliximab treatment in refractory rheumatoid arthritis.Predictors of European League Against Rheumatism (EULAR) good response, DAS-28 remission and sustained responses to TNF-inhibitors in rheumatoid arthritis: a prospective study in refractory disease.Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study.Circulating anti-citrullinated peptide antibodies, cytokines and genotype as biomarkers of response to disease-modifying antirheumatic drug therapy in early rheumatoid arthritis.A personalized medicine approach to biologic treatment of rheumatoid arthritis: a preliminary treatment algorithm.¹H-NMR-Based Metabolomic Study for Identifying Serum Profiles Associated with the Response to Etanercept in Patients with Rheumatoid Arthritis.Rituximab is more effective than second anti-TNF therapy in rheumatoid arthritis patients and previous TNFα blocker failureIn antisynthetase syndrome, ACPA are associated with severe and erosive arthritis: an overlapping rheumatoid arthritis and antisynthetase syndrome.Replication of association of the PTPRC gene with response to anti-tumor necrosis factor therapy in a large UK cohort.Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis populationInvestigating CD11c expression as a potential genomic biomarker of response to TNF inhibitor biologics in whole blood rheumatoid arthritis samples.Loci associated with N-glycosylation of human IgG are not associated with rheumatoid arthritis: a Mendelian randomisation studyCorrelation of C-reactive protein haplotypes with serum C-reactive protein level and response to anti-tumor necrosis factor therapy in UK rheumatoid arthritis patients: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study SImpact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trialEffectiveness of four dynamic treatment strategies in patients with anticitrullinated protein antibody-negative rheumatoid arthritis: a randomised trial.Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy.Differential Methylation as a Biomarker of Response to Etanercept in Patients With Rheumatoid Arthritis.Metabolic profiling predicts response to anti-tumor necrosis factor α therapy in patients with rheumatoid arthritis.Association of HLA-DRB1 haplotypes with rheumatoid arthritis severity, mortality, and treatment responsePreviously reported PDE3A-SLCO1C1 genetic variant does not correlate with anti-TNF response in a large UK rheumatoid arthritis cohort.
P2860
Q24310184-59690F00-CBFF-42F8-8682-9860989748DDQ24627677-C03F8A20-5F5B-43D2-B1E6-E7270E708A6DQ26783657-8939046F-B8C1-4CA0-BDFF-5A11C26CBA72Q27692641-8E6737E3-C033-4865-8596-DD66299F79CBQ28271779-2785B996-1F0F-42FA-9509-9331D0D809DAQ28551566-48966852-D5E8-4203-8595-D5028FFFD6AAQ33627758-2A0899F5-B09C-411E-A821-08488DB16B47Q33731299-43504544-375C-4114-A793-16A198735A72Q33888733-DC4FD621-88D7-4156-8178-B332C2156294Q33893385-61883E7F-BAB1-4D27-A234-FD14E7AA1298Q34070615-7C0987CD-FBC3-4A60-91ED-869058480E6BQ34130318-99E8A6D9-C635-42F1-9B29-28B41A67A1D1Q34216613-3FA8F0B0-06D3-4449-B45F-84D0B67EA490Q34588629-CEC2FD76-138A-48AA-8740-23492128C7DCQ34834289-95101DCB-29DE-406A-BE4A-FD352E548A90Q34886162-784D4B66-B1D6-4D89-980E-DFE57F32890BQ34989977-16E315EE-B41C-436C-9AAB-494538C4F0EEQ35102134-659446E0-6FF0-4057-901F-110ABE251AD4Q35107327-AD6E7667-C16A-43FE-B0D5-14454BFF7D6EQ35221741-71BCD9BE-F929-4171-9418-6B4C56A380FAQ35475541-F22F91FB-2194-4AB7-8958-D5B0FA1E224DQ35577993-1776514C-34EE-49BD-A7E0-07C0F4823A48Q35605438-837062FC-AA76-4415-9768-3D8E33F8D80BQ35645491-E2811AFB-7C7B-4441-81F3-54593079F80AQ35835741-03569E85-B6C6-4E8D-88F7-4A215468231EQ35838512-9FF9460F-8451-40C2-B436-2A9B651CA698Q36108479-C76B964D-E2D6-4C6F-B74B-E0A387802193Q36152934-6E929EF2-9F8F-4184-9E16-48B34B9FC8A1Q36189976-64924B6A-7BB6-40F8-BD4B-8F62E0260811Q36279419-9265475E-E55F-4CCB-99BD-BC46F85A0431Q36439978-8DE1FF34-4B9E-4AB4-A321-21F57E6BFE7DQ36475613-74F44058-4EF7-47E0-B98F-1005CDD23AF5Q36633196-ACC94996-5255-41D9-A48E-7620A20DE8B5Q36761916-DC5BA1F5-2448-4B71-8A3D-5C48D146E685Q36773674-DDCE48FB-9175-4EFE-B2AA-5F8A548274A3Q36839197-01B93CAF-1516-40B0-B254-975E756311FFQ37023870-214C51EF-07A8-4893-8751-3308A0D0C065Q37023883-0E551D9B-7AC9-4179-A8D5-05C03894987BQ37054390-933B73F0-C47B-4144-B43A-DD8D0CEBC3BAQ37200651-17332295-9DA4-4FB9-8C41-E955B9B5E265
P2860
Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 28 March 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Association of rheumatoid fact ...... ponse in rheumatoid arthritis.
@en
Association of rheumatoid fact ...... ponse in rheumatoid arthritis.
@en-gb
Association of rheumatoid fact ...... ponse in rheumatoid arthritis.
@nl
type
label
Association of rheumatoid fact ...... ponse in rheumatoid arthritis.
@en
Association of rheumatoid fact ...... ponse in rheumatoid arthritis.
@en-gb
Association of rheumatoid fact ...... ponse in rheumatoid arthritis.
@nl
prefLabel
Association of rheumatoid fact ...... ponse in rheumatoid arthritis.
@en
Association of rheumatoid fact ...... ponse in rheumatoid arthritis.
@en-gb
Association of rheumatoid fact ...... ponse in rheumatoid arthritis.
@nl
P2093
P2860
P50
P356
P1476
Association of rheumatoid fact ...... ponse in rheumatoid arthritis.
@en
P2093
A G Wilson
A W Morgan
D P M Symmons
K L Hyrich
P2860
P356
10.1136/ARD.2007.084715
P407
P577
2008-03-28T00:00:00Z
P5875
P6179
1009203282